Evidence map›Paper›PMID 30206764›Full record

ArticleJournal of neuro-oncology2018

Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience.

Cassie Kline, S John Liu, Sai Duriseti, Anuradha Banerjee, Theodore Nicolaides, Shannon Raber, Nalin Gupta, Daphne Haas-Kogan, Steve Braunstein, Sabine Mueller

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Reirradiation for diffuse intrinsic pontine glioma: a systematic review and meta-analysis.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2019
    Pooled it
  5. Review
  6. Reirradiation for diffuse intrinsic pontine glioma in an upper middle-income country: does full dose improve outcomes?Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026
    Observational
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Re-irradiation in progressive diffuse infiltrative pontine glioma in children and young adults.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Reirradiation for diffuse intrinsic pontine glioma: prognostic radiomic factors at progression.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cassie KlineDepartment of Pediatrics, University of California, San Francisco, CA, USA. cassie.kline@ucsf.edu.ORCID http://orcid.org/0000-0001-7765-7690
S John LiuSchool of Medicine, University of California, San Francisco, CA, USA.
Sai DurisetiDepartment of Radiation Oncology, Washington University in Saint Louis, St Louis, MO, USA.
Anuradha BanerjeeDepartment of Pediatrics, University of California, San Francisco, CA, USA.
Theodore NicolaidesDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Shannon RaberDepartment of Pediatrics, University of California, San Francisco, CA, USA.
Nalin GuptaDepartment of Pediatrics, University of California, San Francisco, CA, USA.
Daphne Haas-KoganDepartment of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
Steve BraunsteinDepartment of Radiation Oncology, University of California, San Francisco, CA, USA.
Sabine MuellerDepartment of Pediatrics, University of California, San Francisco, CA, USA. sabine.mueller@ucsf.edu.

Funding

Institutional Career Development Core SupplementKL2TR001870 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KANAYA, ALKA M., SARKAR, URMIMALA · 2016 to 2025
$19.7M
Clinical and Transtional Science InstituteKL2TR000143 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$11.9M
Research Training in Childhood CancerT32CA128583 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Eric Alejandro Sweet-Cordero · 2007 to 2026
$6.0M
Cannonball Kids' Cancer Foundation A129749NCATS NIH HHS KL2TR000143NCATS NIH HHS KL2TR001870NCI NIH HHS T32 CA128583
6 · The paper itself

Abstract

backgroundDiffuse intrinsic pontine glioma (DIPG) is a rare, aggressive brain tumor with no known cure. Reirradiation (reRT) at recurrence can prolong survival. The impact of irradiation may be heightened when combined with PD-1 inhibition. We describe our experience using reRT, with or without PD-1 inhibition, in a cohort of patients with recurrent DIPG.

methodsWe performed a retrospective cohort analysis of children who received reRT with or without concomitant PD-1 inhibition for recurrent DIPG at a single institution between 2005 and 2016. We compared progression-free (PFS) and overall survival (OS) between those who received reRT alone or in combination with PD-1 inhibition. We then compared reRT to a cohort of patients who did not receive reRT.

resultsThirty-one patients were included (8-reRT with nivolumab; 4-reRT alone; 19-no reRT). Patients who received reRT had prolonged OS compared to no reRT (22.9 months-reRT with nivolumab; 20.4 months-reRT alone; 8.3 months-no reRT; p < 0.0001). Patients who received reRT with nivolumab vs. reRT only had slightly prolonged OS from diagnosis and from reRT (22.9 vs. 20.4 months for time from diagnosis; 6.8 vs. 6.0 months for time from reRT). All patients receiving reRT with or without nivolumab tolerated the therapy without acute or late toxicity.

conclusionsOur experience demonstrates the tolerability of reRT with concurrent PD-1 inhibition for recurrent DIPG and suggests that combination therapy may offer survival benefit. Future prospective studies are needed to confirm the benefits of this combination therapy.

Indexed as

AdolescentAntineoplastic Agents, ImmunologicalBrain Stem NeoplasmsChildChild, PreschoolFemaleGliomaHumansKaplan-Meier EstimateMaleNeoplasm Recurrence, LocalNivolumabProgrammed Cell Death 1 ReceptorProgression-Free SurvivalRe-IrradiationRetrospective StudiesAntineoplastic Agents, ImmunologicalNivolumabPDCD1 protein, humanProgrammed Cell Death 1 ReceptorDIPGPD-1 inhibitionReirradiationSurvival

Identifiers

PMID30206764

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.